CDSCO panel gives nod for continuation of phase-II clinical trial of SII’s dengue vaccine

New Delhi: An expert committee under the Central Drug Regulatory Authority has recommended continuation of phase II clinical trial of the Serum Institute Of India (SII)’s vaccine against dengue after noting the promising results of the phase-I interim clinical trial.

The Serum Institute conducted the phase-I, double-blind, randomised, placebo-controlled trial on 60 healthy individuals aged 18 to 45 years in Australia to assess safety and immunogenicity of the tetravalent live attenuated DENGUE VACCINE.

A tetravalent live attenuated dengue vaccine was manufactured in India after receipt of vaccine strains from NIAID, NIH, USA.

In light of recommendation of the subject expert committee dated July 18, 2023, the SII presented phase-I interim clinical trial report of Dengue Tetravalent Vaccine (Live, Attenuated) which was discussed by the panel on May 31.

“After detailed deliberation, the committee noted the results of Phase I interim clinical trial and recommended for continuation of Phase II clinical trial as per approved protocol,” the SEC recommendations stated.

Related Posts

  • Pharma
  • July 24, 2025
  • 263 views
Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

  • Pharma
  • July 22, 2025
  • 329 views
DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra